Co-Founder and Chairman of the Investment Committee
Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of Chairman in 2003. Mr. Riggs is also the Managing Member of Balfour Venture Partners, an investment advisor focused on mid-stage healthcare companies. From 1996 to 2000, he was President of Biomatrix, a New York Stock Exchange listed biopharmaceutical company. From 1991 to 1995, Mr. Riggs served as President and CEO of RF&P Corporation, an investment company owned by the State of Virginia Retirement System. Prior to that, Mr. Riggs spent ten years as a member of PaineWebber’s mergers and acquisitions department. Mr. Riggs graduated from Middlebury College and holds an MBA from Columbia University.
Founder & Chief Executive Officer
Formed in 1996, Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors) or, directly, when it partners with life sciences companies to co-develop and co-fund products in late-stage human clinical trials. Prior to founding Royalty Pharma, Mr. Legorreta spent a decade at Lazard Frères in Paris and New York where he provided cross-border merger and acquisition and corporate finance advisory services to European and US corporations. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, and the Boards of Trustees of the Hospital for Special Surgery, the Pasteur Foundation (U.S. affiliate of the French Institut Pasteur), The Open Medical Institute, The Park Avenue Armory and Grace Church School. Mr. Legorreta founded and is currently Chairman of Alianza Médica para la Salud (AMSA), a privately-funded, not-for-profit foundation whose goal is to educate Latin American doctors and healthcare providers to improve the quality of healthcare in Latin America. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City).
Mr. Giuliani has been the President and Chief Executive Officer of Giuliani SpA, a specialty pharmaceutical company operating in Italy and established in 1942, since 2002. He previously held the title of Chief Financial Officer. During his tenure as CEO, Giuliani SpA experienced rapid growth and out-licensed several proprietary drugs, one of which was launched in the US by Shire in 2006. From January 1998 to January 1999, Mr. Giuliani was an investment professional with Vector Fund Management, a private equity firm focused on healthcare and life sciences. Mr. Giuliani also co-founded Mosaix Ventures LP, a private equity fund focused on healthcare and life sciences in 2000, and continues to serve on its Investment Committee. He also serves on several private company boards. Mr. Giuliani holds a degree in economy and commerce from the Catholic University of Sacred Heart and a Masters in corporate finance from Università Commerciale Luigi Bocconi in Milan, Italy.
Mr. Poniatowski currently serves on various boards of Quilvest S.A. (Luxembourg) entities and is notably Chairman of the Board of Quilvest and Partners. Mr Poniatowski is also a board member of International Advisory Services, Terold S.A. (Luxembourg), Grupo Peñaflor (Argentina), Tiendas BBB (Mexico), Chairman of HBM Partners (Zug), of StarTeq Holding (Luxembourg) and of a number of investment companies. He is also Chairman of the non-profit Fondation ARPE in Switzerland. Mr. Poniatowski was a senior banker with Lazard Frères in the United States and in Europe from 1976 through 2003, where he was most recently a Managing Director. While at Lazard, Mr. Poniatowski worked in the mergers and acquisitions and corporate advisory, during which time he was involved with a number of cross border assignments and transactions in Europe, the United States and Latin America. Mr. Poniatowski has a degree in Financial Management from Ecole des Cadres (EDC) in Paris-Neuilly, France.
Mr. Rodriguez-Pastor has been Chairman and CEO of Grupo Interbank since 1995. Interbank is one of Peru’s largest business groups with annual revenue in excess of $2 billion and 20,000 team members. Prior to returning to Peru in 1995, Mr. Rodriguez-Pastor held various management positions with Chemical Bank, PaineWebber, Citibank and Banco Santander in the US from 1983 to 1995. Mr. Rodriguez-Pastor received his BA in social sciences in 1983 from the University of California at Berkeley and his MBA in 1988 from the Amos Tuck School at Dartmouth College.
Dr. De Souza is currently President and Chief Executive Officer of Neuropore Therapies a biopharmaceutical company developing disease modifying treatments for Parkinson’s Disease, Alzheimer’s Disease and other neurodegenerative disorders by targeting molecular mechanisms of autophagy and neuro-inflammation to facilitate clearance of misfolded proteins. He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences, Nasdaq: NBIX) and served as President and Chief Executive Officer of several public (Biodel, Nasdaq: BIOD; Synaptic Pharmaceutical Corp., Nasdaq: SNAP) and private (Archemix) biotech companies. Dr. De Souza has raised several hundred million dollars in capital in private (venture) and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic Pharmaceuticals sale to H. Lundbeck A/S) to provide liquidity and build shareholder value. Over Dr. De Souza’s career, he has also served in a number of high-ranking R&D roles, including Senior Vice President and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and Executive Vice President of Research and Development at Neurocrine Biosciences (1992-1998), and Head of CNS Diseases Research at DuPont Merck (1990 – 1992). He has extensive Board experience and serves or has served on several Editorial Boards and National Institutes of Health Committees as well as Board of Directors of several private companies (Merial, Royalty Pharma, nLife and Psyadon) and public companies including Neurocrine Biosciences (Nasdaq: NBIX), Synaptic Pharmaceuticals (Nasdaq: SNAP), Targacept, Inc., (Nasdaq: TRGT), Palatin Technologies (AMEX: PTN), IDEXX Laboratories (Nasdaq: IDXX), Biodel (Nasdaq: BIOD), Catalyst Biosciences (Nasdaq: CBIO) and Bionomics Limited (Australian Exchange: BNO.AX; current Chairman). Dr. De Souza received his BA (Honors) in physiology and his PhD in neuroendocrinology from the University of Toronto, and received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.
Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate advisory services. From 1989 to 2010, Mr. Norden held various senior positions with Wyeth, most recently as Senior Vice President and Chief Financial Officer. At Wyeth, Mr. Norden was a key member of the primary management and operating committees, Chairman of the Investment Committee and Disclosure Committee, Co-Chairman of the Capital Committee, and an executive member of the R&D Executive Development Council and M&A Committee. Mr. Norden began his career in 1983 with Arthur Andersen & Company working primarily with multinational public and private companies in the Consumer Products and Financial Services industries. Mr. Norden serves on several Boards including: Zoetis, a global leader in discovering, developing, manufacturing and commercializing animal health medicines and vaccines, where he is Chairman of the Audit Committee and Member of the Compensation Committee; NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products, where he is Chairman of the Audit Committee; Welch Allyn, a leading global provider of medical diagnostic equipment, where he is Chairman of the Audit Committee and Member of the Nominating and Governance Committee. Mr. Norden is a former Board member of Human Genome Sciences, serving as Chairman of the Audit Committee until GlaxoSmithKline acquired the company in 2012.